Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 9/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1981068 | 0.82 | PPARG (0.54) | NPC1RAB9APPARAKDM1APPARG | |
| SCHEMBL3530493 | 0.82 | RAB9A (0.53) | NPC1RAB9APPARAKDM1APPARG | |
| SCHEMBL4461142 | 0.81 | KDM4E (0.64) | NPC1RAB9APPARAPPARGKDM4E | |
| SCHEMBL3532628 | 0.81 | KDM1A (0.57) | NPC1RAB9APPARAKDM1APPARG | |
| SCHEMBL4888438 | 0.81 | PPARG (0.57) | NPC1RAB9APPARAKDM1APPARG | |
| SCHEMBL820945 | 0.79 | SMN1; SMN2 (0.51) | NPC1RAB9APPARAPPARGKDM4E | |
| SCHEMBL4885518 | 0.79 | ALDH1A1 (0.49) | NPC1RAB9APPARAKDM1APPARG | |
| SCHEMBL13958893 | 0.78 | KDM4E (0.47) | NPC1RAB9APPARGKDM4EPOLB | |
| SCHEMBL1436917 | 0.77 | PPARA (0.54) | PPARAKDM1APPARGKDM4EPOLB | |
| SCHEMBL1436051 | 0.77 | PPARA (0.51) | NPC1RAB9APPARAPPARGKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476742-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476742-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476742-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-01-13 | — | — | US | disclosed |
| US-20050107392-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107392-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents | GPR119, INSR, IRS1 | NPC1 320/4885RAB9A 3286/4885PPARA 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.